Overview

Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Status:
Recruiting

Trial end date:
2029-06-10

Target enrollment:

Participant gender:

Summary

The study propose to generate a clinical trial based on precision medicine to evaluate the use of immunotherapy in patients with altered homologous recombination repair genes and without progression after prior targeted therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Georges Francois Leclerc

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab
Olaparib
Tremelimumab